DNA-based biomaterials have emerged as powerful platforms for advancing cancer immunotherapy, leveraging their unique programmability, structural precision, and biocompatibility. By enabling rational design at the molecular level, DNA nanostructures, such...
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: